235 East 42nd Street
About Pfizer, Inc.
At Pfizer Worldwide Research & Development (WRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing critical medicines and treatments for patients around the world.
Pfizer’s OWNIT! Culture
Through Pfizer’s shared mission to impact global health, Pfizer has built a unique OWNIT! culture to empower you to play your part in each of Pfizer’s life-changing achievements. So what does OWNIT! mean? It means taking ownership of your career and the contribution you make to the business and the patients and customers impacted by Pfizer’s business. This encouragement for personal progress allows colleagues to treat each other with honesty and respect, to act quickly and decisively, all to deliver results with commitment and care.
Professional Development at Pfizer
Pfizer’s belief that every person matters is also what proves their commitment to you. Whatever your talent or skill, you will be taught how to become an expert in your field through tools like Pfizer’s Mentor Match online tool and creating detailed career “roadmaps” with your manager that take into account your interests and aspirations as well as Pfizer’s business needs. Managers are also encouraged to provide frequent performance feedback instead of relying solely on yearly evaluations. From here, you’ll be inspired to refine – and redefine – your personal and professional goals.
Diversity at Pfizer
Pfizer believes that diversity is just as crucial to building a successful business as it is to building a vibrant culture. Pfizer’s community is one of the greatest building aspects about their culture. And their Diversity and Inclusion team ensures that every colleague experiences a fair and supportive environment. From holding managers and leaders accountable for creating inclusive and equitable workplaces, to helping colleagues appreciate the value of diversity, Pfizer is a place where people from all backgrounds and abilities can build a fulfilling career and reach their full potential.
Finding Your Community and Making a Difference
With more than 95 Colleague Resource Groups (CRGs) located around the world, working at Pfizer means finding a community. Pfizer offers CRGs focused on the following groups: Asians, Blacks, colleagues with disabilities, Latinos, LGBTQ, Veterans and Women. These CRGs offer support, mentoring and networking opportunities to help members enhance their skills and advance their careers. They also help their communities by participating in volunteer and philanthropic activities, from sponsoring student scholarships to health fairs focused on the unique healthcare concerns of diverse populations.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of today. As one of the world’s premier pharmaceuticals companies, Pfizer’s network and influence spans the entire globe. But in every country and continent, Pfizer colleagues are energized by a unique spirit. No matter the role or responsibility, colleagues are empowered by the belief that the work they do has a direct impact on patients.
4078 articles with Pfizer, Inc.
OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced today that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN® (somatropin) for injection, as measured by annual height velocity at 12 months.
10/21/2019When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
10/21/2019Last week was busy for clinical trial news. Here’s a look.
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis
Leaders in atrial fibrillation and wearable technology to develop educational content around atrial fibrillation to help identify and support those at increased risk of stroke
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Use of Dovato in Virologically Suppressed Adults with HIV-1
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a supplemental New Drug Application to the US Food and Drug Administration for Dovato as a switch treatment for HIV-1 infection in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure.
This shortage could force many treating physicians to begin making tough choices on how to address cancers in their patients.
ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology
ImaginAb, Inc. announced the signing of a multi-party collaboration agreement with AstraZeneca, Pfizer Inc. and Takeda Pharmaceutical Company Limited focused on furthering the clinical development of ImaginAb's CD8 ImmunoPET technology.
The drug met all the co-primary and key secondary endpoints related to skin clearance and itch relief compared to placebo.
10/14/2019What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others?
Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis
Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study
Advisory - Some EpiPen and EpiPen Jr auto-injectors may be difficult to remove from their carrier tubes
Consumers and pharmacists should check that devices can be removed from their carrier tubes with ease
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
Akcea and Ionis to earn $250 million license fee
Excelera Network® and Pfizer Partner for Distribution of World's First Oral Treatment for Transthyretin Amyloid Cardiomyopathy
New medication added to list of innovative treatments offered through Excelera Network in Pfizer's limited distribution network
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer
Results to be presented during a late-breaking oral session at the 2019 ESMO Congress and simultaneously published in The New England Journal of Medicine
Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis
Pfizer Inc. announced positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.
Winners of the Pfizer Golden Ticket Program announced last night during a panel discussion and networking event at Pfizer’s Cambridge, MA R&D site
EMD Serono and Pfizer Inc. announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® alone or as part of combination regimens for the treatment of advanced cancers, including renal cell carcinoma, metastatic Merkel cell carcinoma and some other solid tumors at the European Society for Medical Oncology Congress 2019 in Barcelona, Spain.
Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman
Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. announced that Executive Chairman of the Board Ian C. Read has chosen to retire on December 31, 2019, and that it has unanimously elected Pfizer’s Chief Executive Officer (CEO), Dr. Albert Bourla, to succeed him as Chairman of the Board of Directors effective January 1, 2020.
Pfizer announced positive top-line results from the first trial in May.